Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.

Soft copper wire : 20 gauge (wire diameter 0.8mm): 40cm (16 inch) about 5cm for each detail 4 cm (about 1.5 inch) for each ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...

Measures intended to punish elite universities are inflicting collateral damage on the nation’s two-year colleges, which ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according to the Cleveland Clinic. It’s a condition often linked to obesity, ...

Although mighty American pharmaceutical company Eli Lilly (NYSE: LLY) has a dizzying number of commercialized products, it's ...